Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting.
- Author:
Vijay GAYAM
1
;
Muhammad Rajib HOSSAIN
;
Mazin KHALID
;
Sandipan CHAKARABORTY
;
Osama MUKHTAR
;
Sumit DAHAL
;
Amrendra Kumar MANDAL
;
Arshpal GILL
;
Pavani GARLAPATI
;
Sreedevi RAMAKRISHNAIAH
;
Khalid MOWYAD
;
Jagannath SHERIGAR
;
Mohammed MANSOUR
;
Smruti MOHANTY
Author Information
- Publication Type:Original Article
- Keywords: Hepatitis C, chronic; Direct acting antiviral agents; Sustained Virologic response; HCV/HIV coinfection
- MeSH: Antiviral Agents*; Coinfection*; Drug Interactions; Fatigue; Hepacivirus; Hepatitis C*; Hepatitis C, Chronic; Hepatitis*; Humans; Retrospective Studies; Treatment Outcome*
- From:Gut and Liver 2018;12(6):694-703
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: Limited data exist comparing the safety and efficacy of direct-acting antivirals (DAAs) in hepatitis C virus (HCV) monoinfected and HCV/human immunodeficiency virus (HIV) coinfected patients in the real-world clinic practice setting. METHODS: All HCV monoinfected and HCV/HIV coinfected patients treated with DAAs between January 2014 and October 2017 in community clinic settings were retrospectively analyzed. Pretreatment baseline patient characteristics, treatment efficacy, factors affecting sustained virologic response at 12 weeks (SVR12) after treatment, and adverse reactions were compared between the groups. RESULTS: A total of 327 patients were included in the study, of which 253 were HCV monoinfected, and 74 were HCV/HIV coinfected. There was a statistically significant difference observed in SVR12 when comparing HCV monoinfection and HCV/HIV coinfection (94% and 84%, respectively, p=0.005). However, there were no significant factors identified as a predictor of a reduced response. The most common adverse effect was fatigue (27%). No significant drug interaction was observed between DAA and antiretroviral therapy. None of the patients discontinued the treatment due to adverse events. CONCLUSIONS: In a real-world setting, DAA regimens have lower SVR12 in HCV/HIV coinfection than in HCV monoinfection. Further studies involving a higher number of HCV/HIV coinfected patients are needed to identify real predictors of a reduced response.
